ACUR (ACUR) Stock Price & Analysis
ACUR (ACUR) rose 0.00% to USD 0 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
ACUR last closed at USD 0; the session ranged USD 0–0 on volume of 400 shares. Market capitalization is $13,200, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 400 shares |
| Market Cap | $13,200 |
| Exchange | PNK |
Technical Analysis (ACUR)
Nexqual's technical model rates ACUR "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.5 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (ACUR)
Wall Street analysts rate ACUR "None", per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | None |
|---|
Earnings (ACUR)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2017-03-31 | USD 0.03 vs est -0.11 ▲ beat |
| 2016-12-31 | USD 0.13 vs est -0.27 ▲ beat |
| 2016-09-30 | USD -0.19 vs est -0.27 ▲ beat |
| 2016-06-30 | USD -0.28 vs est -0.28 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (ACUR)
| Total Revenue | $1.56M |
|---|---|
| Revenue Growth (YoY) | -95.00% |
| Gross Margin | +2.50% |
| Operating Margin | -658.33% |
| Profit Margin | -56.24% |
| Debt / Equity | 84.27 |
| Current Ratio | 0.72 |
| Total Debt | $150,000 |
| Free Cash Flow | $-1.10M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (ACUR)
Nexqual rates ACUR's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Critical — Revenue -48% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — Debt/Equity 0.8x |
| Cash Flow | Weak — FCF negative: -$1M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ACUR)
| Insider Ownership | +1.69% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 66.00M |
| Float | 64.20M |
| Short % of Float | +1.20% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (ACUR)
ACUR is led by Robert B. Jones (age 66), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.
| CEO, President & Director | Robert B. Jones (age 66) |
|---|---|
| CFO, Senior VP, Treasurer & Corporate Controller | Robert A. Seiser (age 61) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AFFY | AFFYMAX INC | USD 0 | ▲ 0% |
| ANTH | ANTHERA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| BGMD | BG MEDICINE INC | USD 0 | ▲ 0% |
| IMUC | EOM Pharmaceutical Holdings Inc | USD 0.25 | ▲ 17.92% |
| BSPM | Biostar Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.